viewHikma Pharmaceuticals PLC

Hikma Pharmaceutical - Board Committee Changes

RNS Number : 4005E
Hikma Pharmaceuticals Plc
27 February 2020

Hikma Pharmaceuticals PLC - Board Committee Changes



London, 27 February 2020 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (Hikma) Further to our announcement last year that the Board was considering succession for the Senior Independent Director role, we are pleased to announce that Pat Butler has agreed to become the chair of the Nomination and Governance Committee and Senior Independent Director.  Pat's responsibilities for chairing the Audit Committee will be handed over to a new chair, who is being identified.  Robert Pickering, the current Senior Independent Director who has served for nine years, has decided to retire from the Board following the implementation of the changes.  The effective date of the changes will be announced in due course.




-- ENDS --




Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary                                                                 +44 (0)20 7399 2772

Susan Ringdal, EVP Strategy and Global Affairs                                          +44 (0)20 7399 2760


About Hikma


Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Quick facts: Hikma Pharmaceuticals PLC

Price: 2470

Market: AIM
Market Cap: £5.69 billion

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...